Real-World Study Explores Oral Semaglutide Effectiveness in Dutch Type 2 Diabetes Patients

Managing Type 2 Diabetes (T2D) often requires effective glucose-lowering treatments, with convenience being a significant factor for patient adherence. Oral semaglutide, a GLP-1 receptor agonist, offers a non-injectable option for patients. However, real-world data on its performance outside of highly controlled clinical trials is crucial to understand its practical application and effectiveness. This study addresses the knowledge gap by investigating the clinical parameters associated with once-daily oral semaglutide use in a real-world adult population with Type 2 Diabetes in The Netherlands.

This multi-centre study, involving 145 adult patients with Type 2 Diabetes, aimed to observe the real-world effectiveness and safety of oral semaglutide in a routine clinical setting. As a non-interventional study, it collected data on clinical parameters as patients received commercially available oral semaglutide according to local label and physician discretion. While the provided record indicates the study is completed, specific quantitative results detailing changes in HbA1c (a key marker for blood sugar control), body weight, or other metabolic outcomes are not yet available in this abstract. > The primary finding from the study's design perspective is its successful enrollment of a substantial real-world cohort (145 participants) to gather observational data on oral semaglutide's performance outside of controlled trial environments. The study's completion suggests data has been collected for subsequent analysis and publication, which would then reveal the actual impact on glycemic control and patient outcomes.